Intervention not reported
Clinically apparent hepatitis A (Dose of live attenuated HAV vaccine, titre >= TCID50 ) all included trials Dienstag 1999 · patients with preventing hepatitis A.
It is very uncertain whether the intervention changes clinically apparent hepatitis A (Dose of live attenuated HAV… (very low certainty).
1 finding from 1 review
Intervention not reported
Clinically apparent hepatitis A (Dose of live attenuated HAV vaccine, titre < TCID50 ) low risk of bias Dienstag 1999 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes all‐cause mortality compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes adverse events compared with ursodeoxycholic acid (very low certainty).
1 finding from 1 review
Alkaline phosphatase · patients with primary biliary cirrhosis.
1 finding from 1 review
Liver morbidity · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes liver morbidity compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes adverse events compared with no intervention (very low certainty).
1 finding from 1 review
Alkaline phosphatase · patients with primary biliary cirrhosis.
3 findings from 1 review
no estimate extracted
4 studies · 79 participants
Low
no estimate extracted
2 studies · 38 participants
Very low
no estimate extracted
2 studies · 41 participants
Low
Maximum total serum bilirubin (µmol/L); all studies · patients with primary biliary cirrhosis.
1 finding from 1 review
All‐cause mortality · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes all‐cause mortality compared with ursodeoxycholic acid (very low certainty).
1 finding from 1 review
Liver morbidity · patients with primary biliary cirrhosis.
It is very uncertain whether bezafibrate changes liver morbidity compared with ursodeoxycholic acid (very low certainty).
1 finding from 1 review
Mortality ‐ Antibiotics versus no antibiotics · patients undergoing liver resections
1 finding from 1 review
Mortality ‐ Long duration antibiotics versus short duration antibiotics · patients undergoing liver resections
1 finding from 1 review
Mortality ‐ Prebiotics and probiotics versus none · patients undergoing liver resections
1 finding from 1 review
Mortality ‐ Pre‐operative and post‐operative prebiotics and probiotics versus post‐operative prebiotics and probiotics · patients undergoing liver resections
1 finding from 1 review
Mortality ‐ Topical povidone iodine gel versus no topical povidone iodine gel · patients undergoing liver resections
It is very uncertain whether intervention changes mortality ‐ Topical povidone iodine gel versus no topical povidone… compared with comparison (very low certainty).
1 finding from 1 review
60‐day mortality ‐ Aprotinin versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Aprotinin versus control compared with control (very low certainty).
1 finding from 1 review
Thromboembolic episodes ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes thromboembolic episodes ‐ Recombinant factor VIIa (rFVIIa) versus… compared with control (very low certainty).
1 finding from 1 review
Serious adverse events ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes serious adverse events ‐ Recombinant factor VIIa (rFVIIa) versus… compared with control (very low certainty).
1 finding from 1 review
Blood loss ‐ Aprotinin versus control (litre) · Patients with liver transplantation.
1 finding from 1 review